8024 BRIDGE ST NORTH RICHLAND HILLS, TX 76180 Get Directions
8024 BRIDGE ST NORTH RICHLAND HILLS, TX 76180 Get Directions
Encore Vision, Inc. (“Encore Vision” or the “Company”) is an ophthalmic therapeutic company formed to develop a treatment for presbyopia, directed at its primary cause. Encore Vision, Inc. is based in Fort Worth, Texas. Founded in 2000, Encore Vision, Inc. is a Delaware corporation and an affiliate of Encore Health, LLC. (“Encore Health”). Encore Health was founded by Jon Till, M.D. (ophthalmologist), Ronald Blum, O.D. (optometrist) and The Egg Factory LLC (a Virginia based Company that develops and incubates ophthalmic technologies) to pursue their jointly held hypothesis that presbyopia can be treated and/or prevented by reducing the aberrant bonds, which form in the human crystalline lens, resulting in increasing lens stiffness with age. In January 2001, Drs. Till and Blum filed a patent application for this invention, which issued in August 2005. Encore Health formed Encore Vision with financing from private investors, and licensed Encore Vision to develop and commercialize its proprietary technology directed at treating presbyopia.
Encore Vision is developing a “first in class” technology for the treatment of presbyopia. The Company has been well-financed and mentored by leading ophthalmologists and optometrists during its incubation phase. Encore Vision has achieved significant progress in developing extensive Intellectual Property protection. Encore Vision’s technology is covered by a robust and growing patent portfolio which includes one issued broad-based US patent, notice of allowance on a second U.S. patent and more than 40 Pending US and Foreign patent applications and provisional filings, including composition of matter applications for its proprietary formulations. The Company has completed in-vivo proof of concept in an animal model for presbyopia and has begun development activities leading to clinical studies in man.
Encore Vision has its own basic research laboratory dedicated to discovery of compounds and treatment approaches to reverse and prevent presbyopia. The Encore Vision team is staffed to focus on the development of its proprietary compounds and technologies and a development program is well underway to clinically study and gain approval for a first-in-class product to treat presbyopia
© Dun & Bradstreet, Inc. 2025. All rights reserved.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.